Angle PLC Announces Posting of Annual Report and Notice of AGM

Rhea-AI Summary

ANGLE plc (OTCQX:ANPCY), a liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the distribution of its 2024 Annual Report and Financial Statements along with the AGM notice to shareholders. The Annual General Meeting is scheduled for June 30, 2025, at 2:00 pm at the Surrey Technology Centre in Guildford. The company will provide shareholders with a business update following the formal proceedings. The documents are also available on the company's website for review.

GUILDFORD, SURREY / ACCESS Newswire / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2024, and the Notice of Annual General Meeting ("AGM") within it, have been posted to shareholders, and are available on the Company's website.

The AGM will be held at 2:00 pm on Monday 30 June 2025 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded.

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

The Parsortix^® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K₂EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

When and where is ANGLE plc (ANPCY) holding its 2025 Annual General Meeting?

ANGLE plc's AGM will be held on Monday, June 30, 2025, at 2:00 pm at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG.

What documents has ANGLE plc (ANPCY) posted to shareholders?

ANGLE plc has posted the audited Annual Report and Financial Statements for the year ended December 31, 2024, along with the Notice of Annual General Meeting to shareholders.

What is ANGLE plc's (ANPCY) main business focus?

ANGLE plc is a world-leading liquid biopsy company that specializes in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.

Where can shareholders access ANGLE plc's (ANPCY) 2024 Annual Report?

The 2024 Annual Report and Financial Statements are available on the company's website and have been mailed to shareholders.